Decnupaz (pivekimab sunirine-pvzy)
New biologicPriority review
- Region
- 🇺🇸 US
- Active substance
- pivekimab sunirine-pvzy
- Company
- Abbvie Inc
- Status
- Approved
- FDA approval
- Wed 27 May 2026
- Designations
- New biologic, Priority review
- Application
- BLA761460
- Official record
- www.accessdata.fda.gov
Regulatory milestones
Wed 27 May 2026🇺🇸 FDA approval
FDA approves Decnupaz (pivekimab sunirine-pvzy), a new medicine
Abbvie Inc; BLA761460; New biologic, Priority review; vial · source
Follow Decnupaz
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.